Podcasts about bioscience

Colossal Laboratories & Biosciences: https://colossal.com Guests today: Dr. Beth Shapiro and Matt James. _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad To subscribe to my exclusive content on Twitter, please visit my bio at https://twitter.com/GadSaad _______________________________________ This clip was posted on May 5, 2025 on my YouTube channel as THE SAAD TRUTH_1850: https://youtu.be/jlfkuKSurcw _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense.  _______________________________________

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Download the transcript here

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Listen to the podcast here

Bioscience breakthroughs are transforming lives in Central Ohio. From cutting-edge gene therapies to world-first medical devices, the region's life sciences sector is booming—and saving lives. This week's Columbus Metropolitan Club forum brings together scientific leaders and business innovators to explore how research, investment, and clinical development are coming together to power the next generation of healthcare innovation.  Featuring:  Dr. Frank Agbogbo, Vice President of Process Development, Forge Biologics  Dr. Erandi De Silva, Investment Partner, Drive Capital  Dr. Louise Rodino-Klapac, Executive Vice President, Head of R&D, and Chief Scientific Officer, Sarepta  Robin Sears, President and CEO, LENTECHS  The host is Tyler Allchin, Managing Director, Healthcare, JobsOhio This forum was created in partnership with the 2025 COSI Science Festival, and was sponsored by: Armatus Bio, Battelle, Holder Construction, Ohio Life Sciences, The Ohio State University Wexner Medical Center, and Sarepta. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. Our livestream partner was The Columbus Dispatch. This forum was also supported by The Ellis. This forum was recorded before a live audience at The Ellis in Columbus' historic Italian Village on April 30, 2025. 

Dans ce numéro du Journal des biotechs hors série, L'entretien est consacré à Bruno Lafont, cofondateur et PDG de NFL biosciences. NFL Biosciences est une biotech montpelliéraine spécialisée dans le traitement des addictions, et notamment celle au tabac, qui s'est introduite en Bourse en 2021.Bruno Lafont revient notamment sur les données additionnelles récemment publiées sur NFL-101 dans le sevrage tabagique et évoque la poursuite des développements possibles pour l'actif le plus avancé de NFL Biosciences. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Alfredo, Leah and I chat about the recent de-extinction of dire wolves and what it means for the world. Sit back, relax, and enjoy some Happy Fools!Check out Leah's Art: https://www.leahck.com/Buy Trevor's Book: https://a.co/d/fMPgmFEJoin the Happy Fools Chatroom (Discord): https://discord.gg/hgCwDC6PEmail the Happy Fools @ happyfoolspodcast@gmail.com

A few weeks ago, Colossal Laboratories and Biosciences grabbed the world's attention when it announced the de-extinction of the Dire Wolf which last roamed the earth more than 12 thousand years ago, with the successful birth of three animals. Matt James, a long time zoo professional now serving as the company's Chief Animal Officer, discusses the science and technology behind the momentous announcement and the methodology's potential to help conserve extant but endangered species like red wolves. He also addresses some of the misinformation and misunderstanding about what this outcome has and has not achieved and where it   may lead in the future. Animal Care Software

What's the science behind a sweet tooth? James Gallagher explores whether sugar really can be addicted and what happens in our bodies when we want it and when we eat it. He's joined by Professor Susanne Dickson, who specialises in the neurobiology of appetite at the University of Gothenburg, and Professor James Brown from the School of Biosciences at Aston University.With Easter coming up, James meets dental hygienist and researcher Dr Claire McCarthy from King's College London in the BBC loos to get some top tips on keeping our teeth clean and gets a few pointers on where he could do with brushing up on his technique. Presenter: James Gallagher Producers: Tom Bonnett and Hannah Robins Assistant Producer: Anna Charalambou

S4:E167 First is The Weekly Update followed by an interview with Saksham Narang, Co-Founder and Vice President of Yuva Biosciences, a longevity startup focused on mitochondrial science to address aging-related conditions. Yuva has developed topical solutions for hair loss, skin wrinkles, and other aging conditions linked to declining mitochondrial function. The company's approach involves identifying molecules that can restore mitochondrial function, as demonstrated by their ingredient Y100. They produce Y100 in-house and then encapsulate it into a silica particle (Zpods) for extended release in the skin. They've had strong market adoption of their first OTC product through multiple channel partners and are developing several new products to expand their market penetration to Nutraceuticals for more systemic benefits. Yuva follows a partner licensing model where Yuva provides the encapsulated Y100 in bulk and the partner integrates Y100 into their existing product(s). (interview recorded 4.9.25)Listen to the All-In Pod Science Corner segment by David Friedberg on therapy for  mitochondrial dysfunction at 1:26:44Follow David and Paul: https://x.com/DGRollingSouth https://x.com/PalmettoAngel Connect On LinkedIn: https://www.linkedin.com/in/davidgrisell/ https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com. Learn more about RollingSouth at rollingsouth.vc or email david@rollingsouth.vc.

On this episode of The Medical Alley Podcast, we have a conversation with Courtney Jones, Director of Commercial Development at Nu-Tek BioSciences.As the only completely animal-free peptone manufacturing site in the United States, Nu-Tek BioSciences is paving the way for sustainable and effective drug development. Courtney dives into the work Nu-Tek BioSciences is doing, its new manufacturing facility in Austin, MN, and the future of innovation in the biotech space.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

Zaterdag 19 april:Het agrotechbedrijf APIX Biosciensces uit het West-Vlaamse Wingene heeft een wereldprimeur beet: het is er als eerste in geslaagd volwaardige voeding voor bijen te maken.In Amsterdam werd eergisteren het boek Provotyping van de Belgische coach en schrijver Stefaan Vandist uitgeroepen tot Managementboek van het Jaar. Dat is een prijs van de website managementboek.nl. Vandist was trouwens de enige Belg op de shortlist.  Z 7 op 7 is de nieuwe dagelijkse podcast van Kanaal Z en Trends. Elke ochtend, vanaf 5u30 uur luistert u voortaan naar een selectie van de meest opmerkelijke nieuwsverhalen, een frisse blik op de aandelenmarkten en een scherpe duiding bij de economische en politieke actualiteit door experts van Kanaal Z en Trends.Start voortaan elke dag met Z 7 op 7 en luister naar wat echt relevant is voor uw business, onderneming, carrière en geld.

For this episode of BioScience Talks, we're joined by Marco Malavasi, plant ecologist and cartographer at the University of Sassari, in Italy. We discussed his recent BioScience article "Beyond crisis and grief: Rethinking conservation narratives," which serves as a guide to more productively communicating about—and thinking about—conservation in a rapidly changing world. 

Talking Aliens, UFOs, Biosciences and way weirder stuff Don't miss this one HEROparanormal.com

Professor Hank Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He is also the Director of the Stanford Center for Law and the Biosciences. He talks about his career path into bioethics and ethical considerations for organoids, bodyoids, and embryo models. He also discusses the potential future of reproduction, including gametogenesis, ectogenesis, and genetic selection and editing of embryos.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company's new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology. Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture. The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow's lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA. Leire also emphasised that the collaboration is scalable across Genflow's pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases. For more interviews like this, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch

Scientists have resurrected the long-extinct dire wolf after 11,000 years, sparking fierce ethical debates over the limits of genetic science.

*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.BEST OF: A new study warns and threatens that nearly all marine species will be extinct in 80 years. Conveniently Australian researchers and U.S. company Colossal Biosciences announced a plan to perform acts of necromancy and bring extinct species back from the dead. These include the Tasmanian tiger and even a wooly mammoth. A long time ago environmentalists were actually concerned about clean water, organic food, and leaving nature alone. Now the enviro-necromancers advocate for genetically modified animals, plants, and humans, and are eager to defy God in resurrecting creatures that do not even belong within our time period. Others are resurrecting dead pigs with 'sludge' pumped into their systems like a horror movie. This is truly an abomination of nature, a desecration of reality, wherein chimeras and hybrids usurp the natural order.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKMAIN WEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tst-radio--5328407/support.

*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.Colossal Biosciences has announced the successful resurrection of a set of Dire Wolves that have officially been extinct for 10-13,000 years. Time Magazine reported how the company can now “summon back species from the dead,” which “could prevent existing but endangered animals from slipping into extinction themselves.” Colossal Biosciences plans to birth a Mammoth by late 2028, having already in March announced it had copied mammoth DNA to create a woolly mouse,” which is admittedly a “chimeric critter.” In other words, as with the dire wolves, it's a mix of various pieces merged into one, i.e., it's a manmade creation. As Time reports, the company “rewrote the genetic code of the common gray wolf to match it [dire wolf], and, using domestic dogs as surrogate mothers,” resurrected the dead. Since April is the anniversary of the founding of the city of Rome in roughly 753 BCE it's all the more interesting that the company name their wolves after Romulus and Remus. One question is left unaddressed among the spectacle, magic, science, and obvious questions of morality or playing god: how do we define extinction or endangered. It's simple; the International Union for Conservation of Nature (IUCN), which once defined the former term as an animal not spotted in 50 years, now says an animal is extinct if there is “no reasonable doubt that the last individual member has died.” Better yet, these observations are often made not by the IUCN, but by citizens, as is common for bird watchers. The conservation status of each animal, plant and fungi species is compiled by the IUCN in what is called the "Red List,” which has over 41,000 species. And it is this arbitrary list which gives moral licensing and justification to those like Colossal Bioscences.  -FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKMAIN WEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tst-radio--5328407/support.

What’s trending on socials? Digital Content editor Barbara Friedman joins us in studio to give us the scoop See omnystudio.com/listener for privacy information.

Guest: Dr. Shi En Kim Fungi are everywhere—from forests to deserts to cities to Star Trek! Science journalist Dr. Shi En Kim beams back aboard to talk about some of the latest developments in fungal research. "Can Fungi Save This Endangered Hawaiian Tree?" by Shi En Kim for Smithsonian Magazine: https://www.smithsonianmag.com/science-nature/can-fungi-save-this-endangered-hawaiian-tree-180985171/ "Why scientists are enlisting fungi to save endangered plants" by Shi En Kim for Knowable Magazine: https://knowablemagazine.org/content/article/food-environment/2025/mycorrhizal-fungi-help-save-endangered-plants-ecosystems "Biocrusts: The secret world living at the surface of drylands" by Shi En Kim for BioScience: https://academic.oup.com/bioscience/advance-article/doi/10.1093/biosci/biae119/7927803 "The Netherlands' Surprising Bus Stop Bounty" by Shi En Kim for bioGraphic: https://www.biographic.com/the-netherlands-surprising-bus-stop-bounty/ Follow us on Bluesky! Mike: https://bsky.app/profile/miquai.bsky.social Kim: https://bsky.app/profile/goesbykim.bsky.social

In this episode of Careers in Discovery, we're joined by Søren Bregenholt, CEO of Alligator Bioscience, a company developing tumour-directed immunotherapies to treat aggressive cancers such as pancreatic cancer. Søren shares his journey from academic immunologist to biotech CEO, including pivotal moments in his career - from his experiences at the Pasteur Institute, to building his Biotech education at Symphogen, to navigating the corporate world at Novo Nordisk. He reflects on lessons learned from leadership, fundraising, and decision-making at the top, and the importance of humility, structure, and courage in the face of uncertainty. We also explore what it really means to be a CEO, why "solving problems is your job," and how to strike the balance between hierarchy and creativity in growing Biotech companies. A compelling conversation about resilience, reinvention, and leading with clarity in an ever-evolving industry.

Fala Carlão conversa com Eduardo Monteiro, Country Manager da Mosaic, direto da FEMEC, em Uberlândia, na maior feira agro de Minas Gerais. Eduardo destacou a importância de estar sempre presente onde a agricultura acontece de verdade: no campo, ao lado de quem produz. Comentou sobre o impacto positivo da linha Biosciences, que completou um ano desde o lançamento, trazendo inovação com foco em produtividade e sustentabilidade. Ele também reforçou o compromisso da Mosaic com temas globais, como a COP30, e a necessidade de usar insumos de altíssima qualidade para enfrentar os desafios do agro com eficiência e responsabilidade. Fala aí, Eduardo!

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company's differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company's biotech positioning. For more company updates, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments.  Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s."  "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia."  #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Download the transcript here

Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments.  Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s."  "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia."  #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Listen to the podcast here

Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to separate the placebo effect from the effects of the drug. Enveric addresses the promise of neuroplastic drugs that stimulate the neural connectivity between the prefrontal cortex and amygdala without hallucinations. Joe explains, "And the problem, endemic to hallucinogenic psychedelics, is that there's no question in the patient's mind, in the doctor's mind, in everybody's mind whether or not they got an hallucinogenic agent. And so when everybody knows whether they got it or not, that's what you call functional unblinding. And so the FDA was very concerned about this. They said you must be able to separate the placebo from the actual drug. Until we see data that gives us confidence that you separated it, we can't approve it, even though it looks like a very positive impact for the patients." "We were looking precisely to see if we could remove the hallucination without removing the benefit. So that's the field we're in. What's it being called right now? It's a very, very new field being called the non-hallucinogenic neuroplastogen- neuroplastogen indicating that it induces neuroplasticity, in other words, rewiring of the brain, but does so without inducing hallucination. We saw two challenges coming: How do you separate placebo from non-placebo effect and the treatment?" "Then the idea would be, hopefully, this psychedelic treatment was so impactful, you didn't need to take any other treatment again for a long period of time. And that seems pretty aspirational, honestly, and likely to get in the way of real patient acceptance that you want something which is not so sort of rock your world. Most people don't want that. They like to be able to have a drug that is like, take an aspirin. You take it every day. You don't have a big impact. You can go about your life. You don't really notice it other than you feel better. And that's the idea behind the non-hallucinogenic neuroplastogen. It fits much more in line with what patients are looking for and expecting and doctors, the whole healthcare system. It just makes a lot more sense." #MentalHealth #MentalHealthDisorders #MentalHealthEpidemic #Depression #Anxiety #PTSD #Neuroplastogens #Psychedelics  enveric.com Download the transcript here

Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to separate the placebo effect from the effects of the drug. Enveric addresses the promise of neuroplastic drugs that stimulate the neural connectivity between the prefrontal cortex and amygdala without hallucinations. Joe explains, "And the problem, endemic to hallucinogenic psychedelics, is that there's no question in the patient's mind, in the doctor's mind, in everybody's mind whether or not they got an hallucinogenic agent. And so when everybody knows whether they got it or not, that's what you call functional unblinding. And so the FDA was very concerned about this. They said you must be able to separate the placebo from the actual drug. Until we see data that gives us confidence that you separated it, we can't approve it, even though it looks like a very positive impact for the patients." "We were looking precisely to see if we could remove the hallucination without removing the benefit. So that's the field we're in. What's it being called right now? It's a very, very new field being called the non-hallucinogenic neuroplastogen- neuroplastogen indicating that it induces neuroplasticity, in other words, rewiring of the brain, but does so without inducing hallucination. We saw two challenges coming: How do you separate placebo from non-placebo effect and the treatment?" "Then the idea would be, hopefully, this psychedelic treatment was so impactful, you didn't need to take any other treatment again for a long period of time. And that seems pretty aspirational, honestly, and likely to get in the way of real patient acceptance that you want something which is not so sort of rock your world. Most people don't want that. They like to be able to have a drug that is like, take an aspirin. You take it every day. You don't have a big impact. You can go about your life. You don't really notice it other than you feel better. And that's the idea behind the non-hallucinogenic neuroplastogen. It fits much more in line with what patients are looking for and expecting and doctors, the whole healthcare system. It just makes a lot more sense." #MentalHealth #MentalHealthDisorders #MentalHealthEpidemic #Depression #Anxiety #PTSD #Neuroplastogens #Psychedelics  enveric.com Listen to the podcast here

What happens when your own health journey leads you to discover groundbreaking wellness solutions? In this episode of #TheLongevityPodcast, Dr. Jen sits down with Dr. Kim Catherine Grom, a certified IHT wellness practitioner, licensed coach, and nutrition advisor. Dr. Kim shares her battle with late-stage Lyme disease and toxic mold exposure, which led her to seek alternative healing methods beyond traditional medicine. Through her practice, Bioscience for Believers, she now helps others using bio-scans and frequency testing to support wellness without venturing into new age or mysticism. This conversation is a deep dive into resilience, faith, and integrative health solutions that can transform lives.Dr. Kim Catherine Grom is a certified IHT wellness practitioner, licensed coach, and nutrition advisor. After battling late-stage Lyme disease and toxic mold exposure, she discovered alternative healing methods that transformed her health. Through Bioscience for Believers, she now helps others find balance using bio-scans and frequency testing.Facebook:https://www.facebook.com/kimcgrom#Instagram:https://www.instagram.com/kimgrom/Linkedin: https://www.linkedin.com/in/drkimgrom/Website: https://www.lifeconnectionswellness.com/PODCAST Thank you for listening please subscribe and share! - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Shop supplements: https://healthybydrjen.shop/ CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites WATCH THIS:https://www.youtube.com/watch?v=2lSyAFy5U4U&list=PLaDiqj0yz1eeCOATXPoUDt8HEJxz1_lfW - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FOLLOW ME: Instagram :: https://www.instagram.com/integrativedrmom/ Facebook :: https://www.facebook.com/pflegmed Tik Tok :: https://www.tiktok.com/@integrativedrjen YouTube :: https://www.youtube.com/@integrativedrmom - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not spons...

Earlier this month an American bioscience company revealed their genetically engineered woolly mouse, which they described as a step towards bringing the woolly Mammoth back to life. Colossal Biosciences say they edited the genes of mice to replicate the same long, curly hair of Mammoths with the hope of transferring this science to Asian Elephants. RNZ understands Colossal Biosciences also has its sights on the Moa. But as Victor Waters explains, experts here say bringing back the Moa is a no go.

For this episode of BioScience Talks, we're joined by John Bates, Curator of Birds at the Field Museum, Sushma Reddy, Breckenridge Chair of Ornithology at the University of Minnesota and the Bell Museum, and Rachael Herman, Postdoctoral Research Fellow at Stonybrook University.  Our guests were here to chat about a recent research trip to the Falkland Islands, and more specifically, about the gentoo penguins they were studying on those islands.  Pictures from the trip can be viewed on YouTube. Be sure to check out the fantastic Birds of a Feather Talk Together podcast, cohosted by guest John Bates. Learn more about island vegetation restoration at Roots in the Ground, which describes the work of Giselle Hazell, discussed in the episode.

Synopsis: Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech. With four ongoing Phase 1 trials in lymphoma, multiple myeloma, AML, and lupus, Caribou is leading the charge in making CAR T therapies more scalable, accessible, and cost-effective. Rachel also discusses Caribou's journey from a private startup to a publicly traded company, the role of strategic partnerships like Pfizer's equity investment, and how biotech companies can navigate today's uncertain funding landscape. She reflects on lessons from co-founding Caribou at just 26, the evolution of biotech entrepreneurship, and why raising more capital than you think you need is crucial. Plus, she shares her perspective on leadership, industry trends, and the importance of diversity in biotech, as seen during JPMorgan's ‘Pink Tuesday' movement. From cutting-edge science to strategic decision-making, this episode is packed with insights for biotech professionals, investors, and anyone fascinated by the future of gene editing and cell therapy. Biography: Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company's inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.

Research estimates the global animal health market to be roughly $8 billion, a number analyst firm Grand View Research expects to grow at a 10% compounded annual growth rate through 2030. Much of that growth will be driven by biotechnology. Dr. Todd Zion, CEO and founder of Akston Biosciences, joins this week to help understand what is happening in the biotech markets, specifically as it relates to companion animal innovation. We get into: Where the market sits today and how it is evolving Akston Biosciences' 2024 partnership announcement with Purdue University's College of Veterinary Medicine focused on a therapeutic for canine oncology His approach to animal health innovation through precision proteins creating affordable, effective treatments for companion animals What sits in the Akston Biosciences pipeline currently and the company's approach to cost-effectiveness while also staying innovative Todd's past work in human health, how he sees two sides – animal and human health – coming together to push innovation further, faster The regulatory hurdles faced by both human and animal health innovators that delay getting safe, effective treatments to market A big need for more risk capital coming into the animal health innovation market

Research estimates the global animal health market to be roughly $8 billion, a number analyst firm Grand View Research expects to grow at a 10% compounded annual growth rate through 2030. Much of that growth will be driven by biotechnology. Dr. Todd Zion, CEO and founder of Akston Biosciences, joins this week to help understand what is happening in the biotech markets, specifically as it relates to companion animal innovation. We get into:  Where the market sits today and how it is evolving Akston Biosciences' 2024 partnership announcement with Purdue University's College of Veterinary Medicine focused on a therapeutic for canine oncology His approach to animal health innovation through precision proteins creating affordable, effective treatments for companion animals What sits in the Akston Biosciences pipeline currently and the company's approach to cost-effectiveness while also staying innovative Todd's past work in human health, how he sees two sides – animal and human health – coming together to push innovation further, faster The regulatory hurdles faced by both human and animal health innovators that delay getting safe, effective treatments to market A big need for more risk capital coming into the animal health innovation market  

On this episode of the Somewhat Frank Podcast, Frank Gruber (X and IG: @FrankGruber), John Guidos (IG: jgoodtimes83), and Simon Kahan (IG: @simonkahan) discuss the following topics:   We are hosting the Established House in Austin on Friday, March 7th, with a couple of featured conversations, a barista spinning our delightful lattes and teas and lots of opportunities to connect with one another. If you'll be in Austin, please join us! RSVP at: est.us/house25    AI Is Changing How Silicon Valley Builds Startups - The traditional Silicon Valley model of heavy fundraising and large headcounts is being replaced by AI-driven efficiency, with companies like Anysphere and ElevenLabs reaching $100M revenue with under 50 workers. Also, here is Frank's take on it: https://www.linkedin.com/feed/update/urn:li:activity:7299885251869196288/    Mice have been genetically engineered to look like mammoths - Colossal Biosciences genetically engineered mice with mammoth-like fur by altering up to five genes, though only one matches the mammoth genome exactly. Here are some more thoughts on the animal/human hybrid topic: https://www.scientificamerican.com/article/japan-approves-first-human-animal-embryo-experiments/   Digg is coming back, thanks to its founder Kevin Rose — and Reddit's success - Digg is relaunching with Kevin Rose as chair, Alexis Ohanian as an adviser, and Justin Mezzell as CEO, aiming to revive its “homepage of the internet” legacy.   A Private Space Mission Just Successfully Landed on the Moon for the First Time - Firefly Aerospace's Blue Ghost lunar module became the first private company's lander to successfully touch down on the moon, landing on March 2, 2025.   We also upload our episodes to YouTube in video format so you can see us now. Check it out on Established YouTube, where you can subscribe to get updates when we drop a new episode at: https://soty.link/ESTYouTube    As always, thank you for listening, and feel free to reach out and let us know what you think at: somewhatfrank@est.us 

For this episode of BioScience Talks, we're joined by Aspen Ellis, PhD candidate at University of California, Santa Cruz, for a discussion of the largest academic strike in history and a recent BioScience article on the topic.

Professor Rohit Srivastava shares his vision of transforming India through a 10X innovation mindset, prioritizing patents over papers, and building product-focused ecosystems that turn academic research into market solutions.5-point Episode SummaryThe 10X Impact Framework: Prof. Srivastava's approach to creating 10 times more value through patents, startups, and reaching more patients than conventional academic labs.Patents Over Papers: How filing 250+ patents and co-founding 15 startups is transforming academic research into market solutions for India.Building Innovation Ecosystems: Creating bio-clusters across India to connect universities and accelerate product development through interdisciplinary collaboration.Product-First Thinking: Training students to identify market needs and develop solutions that can reduce India's ₹90,000 crore medical device import bill.From Innovation to Impact: The vision to create thousands of "innovation builders" who will transform India from a service economy to a product powerhouse by 2047.Timestamps00:03:37 - 00:05:56 Mentors Who Shaped My Vision for India 00:05:56 - 00:08:55 India's Forward-Thinking Academic Leaders 00:08:55 - 00:11:47 Making Maximum Impact with Minimum Resources00:11:47 - 00:15:00 Patents vs Papers: The Future of Innovation 00:15:00 - 00:18:03 Why Product-First Thinking Changes Everything 00:18:03 - 00:21:39 The Product-First Mindset Behind Innovation 00:21:39 - 00:25:25 The 10X Impact Framework for Success 00:25:25 - 00:28:47 Building NanoBIOS - an Innovation Ecosystem in Academia 00:28:47 - 00:35:02 Transforming Students into Innovators 00:35:02 - 00:38:52 Why Interdisciplinary Thinking Creates Better Products 00:38:52 - 00:42:04 Cross-Pollinating Innovation with Bioclusters Across Universities00:42:04 - 00:45:02 How Patents Create a Virtuous Cycle of Innovation 00:45:02 - 00:49:08 Advice for Young Academics: Be Innovation Builders 00:49:08 - 00:49:43 Can India Create Its Own Philips or Siemens? 00:49:43 - 00:50:08 What is Success? 00:50:08 - 00:50:29 Advice for 18-Year-Olds in University Today 00:50:29 - 00:51:01 The Best Advice I've Ever Received 00:51:01 - 00:51:54 My Dream Dinner with Innovation Giants 00:51:54 - 00:52:27 The 10X Thinking That People Find Hard to AcceptSelected Links and Show NotesSubscribe to our Weekly NewsletterAbout Prof. Rohit SrivastavaProfessor Rohit Srivastava is a pioneering academic entrepreneur who holds the Himanshu Patel Chair at IIT Bombay's Department of Biosciences and Bioengineering. Known for his revolutionary "10X impact" philosophy and "patents over papers" approach, he has filed over 250 patents and co-founded more than 15 startups in just 19 years. His Nanobios Lab has commercialized numerous affordable medical technologies including UChek (a mobile urine analysis system) and Suchek (an indigenous low-cost glucometer), helping reduce India's dependence on imported medical devices.Honored with the prestigious Shanti Swarup Bhatnagar Prize (2021) and the inaugural Vigyan Shri Award (2024), Prof. Srivastava is transforming how academic research translates to market solutions. This episode was made possible by the great folks at Effortless.Effortless has been designed to be user-friendly, aiding you in your journey to streamline financial tasks. Experience the convenience of achieving e-Invoicing and E-way Bill Generation in just a couple of clicks, simplifying your business processes.#10xImpact, #InnovationIndia, #PatentsOverPapers, #ProductFirstThinking, #StartupEcosystem, #MedicalInnovation, #MakeInIndia, #FrugalInnovation, #IITBombay, #HealthTech, #BioTech, #AcademicEntrepreneurship, #IndianInnovation, #ViksitBharat, #TechForHealth

This week on Careers in Discovery, we spoke with Graham Dempsey, CSO of Quiver Bioscience, to talk about his journey from a passion for sports medicine to leading a company at the cutting edge of neuroscience drug discovery. Graham shared how Quiver is combining stem cell models, optogenetics, and AI to study brain diseases at an unprecedented scale, and what he's learned from spending over a decade growing within the same company, from Senior Scientist to CSO. We also explored the realities of Biotech growth, the challenges of translating research into real-world impact, and why persistence is key to success in this space. A fascinating insight into the future of brain-targeted drug development.

Discover the incredible engineering and visionary potential of Bernal Spheres, futuristic space habitats designed to sustain human life in the stars.Watch my exclusive video Big Alien Theory https://nebula.tv/videos/isaacarthur-big-alien-theoryGet Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthurGet a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isaacarthurUse the link gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $30.Visit our Website: http://www.isaacarthur.netJoin Nebula: https://go.nebula.tv/isaacarthurSupport us on Patreon: https://www.patreon.com/IsaacArthurSupport us on Subscribestar: https://www.subscribestar.com/isaac-arthurFacebook Group: https://www.facebook.com/groups/1583992725237264/Reddit: https://www.reddit.com/r/IsaacArthur/Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.SFIA Discord Server: https://discord.gg/53GAShECredits:Megastructures: The Bernal SphereEpisode 485; February 6, 2025Written, Produced & Narrated by: Isaac ArthurEditors: Ludwig LuskaGraphics: Bryan Versteeg, Fishy Tree, Jeremy Jozwik, Udo SchroeterSelect imagery/video supplied by Getty Images Music Courtesy of Epidemic Sound http://epidemicsound.com/creatorPhase Shift, "Forest Night"Chris Zabriskie, "Unfoldment, Revealment", "A New Day in a New Sector"Stellardrone, "Billions and Billions"See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of SCW for Pharma, host Evren Ozkaya welcomes Bryan Holmes, Vice President of Information Technology at Andelyn Biosciences, to discuss the evolving role of IT in pharmaceutical manufacturing and the transformative impact of digitalization on Contract Development and Manufacturing Organizations (CDMOs). The conversation begins with a deep dive into the fundamental differences between traditional pharmaceutical manufacturing and the rapidly growing field of cell and gene therapy, a market that exceeded $5 billion in 2024 and sustains an annual growth rate of over 25%. Bryan explains how these personalized treatments, often targeted for rare diseases and small patient populations, require an entirely new approach to manufacturing, one that prioritizes agility and responsiveness. Evren and Bryan explore how IT strategy plays a pivotal role in modern pharma operations. They discuss the challenges of digital transformation, from ensuring regulatory compliance and data security to bridging communication gaps between CDMOs and their clients. Bryan highlights the ongoing shift toward data sharing, transparency, and accountability in CDMO partnerships—critical for optimizing production processes. The discussion then shifts to the cost-benefit analysis of digitalization, weighing Software-as-a-Service (SaaS) solutions against customized approaches. Evren emphasizes that while change management is difficult, companies that invest in digital transformation today will secure a long-term competitive advantage, as the pharma shop floor is poised for dramatic evolution over the next two decades. Looking ahead, Bryan and Evren explore AI's biggest opportunities in pharma. From automating routine tasks to enhancing quality assurance, AI-driven solutions are unlocking new efficiencies. Bryan underscores that the younger workforce expects technology-driven workplaces, making digitalization not just a competitive edge but a necessity for attracting top talent. Evren and Bryan wrap up their discussion with a call to action: embracing IT and digital transformation is no longer optional but essential for pharma companies looking to stay ahead in an industry evolving at an unprecedented pace.

Plastics can stay around for ages after being discarded. Han Xiao, director of SynthX Center and associate professor within the department of chemistry at Rice University, discusses a possible solution. Han Xiao serves as the Director of the SynthX Center and holds the position of Associate Professor within the Department of Chemistry, Biosciences, and Bioengineering […]

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cell therapy and the challenges associated with navigating a biotech from platform development to lead candidate status -- including staffing up for and funding the journey. Don't miss this episode, recorded in-person in San Francisco. The 2025 BoB@JPM series is supported by Aslton & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Bits of Bennu have building blocks of lifeNASA's OSIRIS-REx mission took six years to travel to the asteroid Bennu and return samples to Earth. Now, the first results from the analysis of these rocks are being released. Researchers found evidence of salty water, as well as the elements necessary for life, such as amino acids and the building blocks for RNA and DNA. We spoke with Kim Tait, senior curator of mineralogy at the Royal Ontario Museum in Toronto, and co-author of one of the recent studies, published in the journal Nature.Unlocking the secret of Polar bear de-icingPolar bears spend so much time going in and out of the water that they are considered marine mammals. So when they do this in the frozen Arctic, why are they not covered in ice? A new study reveals the secret turns out to lie in the unique oils they produce that covers their white fur. Julian Carolan, a PhD candidate at Trinity College Dublin, worked with scientists in Norway, Denmark and the U.K. on this paper published in the journal Science Advances.Truffle-hunting dog finds fabulous new fungusA chance discovery has turned out to reveal a new species of North American truffle. These fungi can be desirable and valuable delicacies. An American truffle hunter, Lois Martin, and her  trained dog Monza found a distinctive truffle in a city park that turned out to be a fungus new to science. Although native to North America, it was more similar to European truffles than any found in the Americas. Dr. Greg Bonito at Michigan State University named this new truffle Tuber canirevelatum,  meaning the ‘dog-found' truffle in honour of Monza and other dogs who look for truffles. The work was published in the journal Mycologia.  Voiding your bowels can improve cognitive performanceTo maximize your cognitive function, it might be a good idea to make sure you have a poo first. That's according to a recent study in the journal Sports Medicine and Health Science. In it, scientists found that 9 out of 13 individuals improved how well they did in a mentally taxing cognitive test if they defecated first, whereas all 13 of them improved in their performance when they took a mild laxative the night before. Chia-Hua Kuo, a professor of sports medicine and nutrition at the University of Taipei, said they also saw an increase in oxygen consumption in the test subjects' subnavel regions as they were doing the test, suggesting a previously unsuspected link between the rectum and the brain. Saving species on Earth, preserving them on the moonThe world is in a biodiversity crisis. We're losing species at an unprecedented rate, thanks to climate change, habitat loss, overexploitation and more. We look at some of the more out-of-the-box solutions that are currently in the works – from creating an internet of animals to monitor biodiversity, to saving samples of Earth's biological resources on the moon.We spoke with:Martin Wikelski, the director of the Max Planck Institute of Animal Behavior, honorary professor of ornithology at the University of Konstanz, and the scientific head of the ICARUS project.Mary Hagedorn, a senior research scientist at the Smithsonian Conservation Biology Institute and senior author of a recent paper published in the journal Bioscience proposing a passive biorepository on the moon.

This good news podcast is all about bringing people together - from heartwarming moments in U.S. politics, to the power of music in children's television, Sam and Billi have a rundown of the four news stories from the week that will make you smile. Hosts: Sam Koslowski and Billi FitzSimonsProducer: Orla Maher Want to support The Daily Aus? That's so kind! The best way to do that is to click ‘follow’ on Spotify or Apple and to leave us a five-star review. We would be so grateful. The Daily Aus is a media company focused on delivering accessible and digestible news to young people. We are completely independent. Want more from TDA?Subscribe to The Daily Aus newsletterSubscribe to The Daily Aus’ YouTube Channel Have feedback for us?We’re always looking for new ways to improve what we do. If you’ve got feedback, we’re all ears. Tell us here.See omnystudio.com/listener for privacy information.

Akston Biosciences is revolutionizing pet healthcare through innovative protein engineering and biotechnology solutions. After selling his first company Smart Cells to Merck for over $500M, Todd Zion founded Akston Biosciences in 2011 to apply advanced biotech expertise to the growing pet health market. With over $50M in funding, Akston is developing breakthrough treatments including once-weekly insulin, cancer therapies, and other protein-based medicines for pets, while maintaining cost effectiveness for pet owners. Topics Discussed:  The transition from human health biotech to the pet health market  Streamlined clinical trial processes in pet health vs. human health  The evolution of the pet healthcare market and consumer willingness to pay  Balancing technical innovation with cost-effective development  The challenges of fundraising in an emerging biotech category  Pipeline development across multiple pet health conditions   GTM Lessons For B2B Founders:  Navigate pivots decisively: Todd emphasized that most founders wait too long to pivot. He advises that when you start seeing signs that the future isn't unfolding as planned, that's the time to begin considering a pivot - while you still have resources and before becoming too entrenched. Their pivot to focusing entirely on pet health required significant restructuring but ultimately created a clearer path forward. Find the regulatory sweet spot: Akston discovered that pet health offered a faster path to market validation compared to human health biotech. The ability to conduct field trials with just hundreds rather than thousands of subjects, combined with more streamlined regulatory requirements, allowed them to de-risk their assets more quickly and cost-effectively while still maintaining high standards. Build for the actual market conditions: Rather than assuming future market changes (like expanded pet insurance coverage), Akston designs their products around current market realities - namely that most pet medications are paid out-of-pocket. This forced them to innovate not just technically but in development and manufacturing to keep costs accessible to pet owners. Create new categories through technology translation: Instead of building an entirely new technology, Akston applied proven biotech approaches from human health to the pet market. This allowed them to leverage existing expertise while pioneering a new category, positioning themselves as "the Biogen for pets" rather than just another pet health company. Structure early testing for rapid validation: By utilizing the FDA's investigational new animal drug application process, Akston could begin testing in their target population much earlier in development. This enabled them to validate their concepts within a year rather than waiting through multiple phases of trials, allowing for more efficient resource allocation.     //   Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe.  www.GlobalTalent.co    

Shift Bioscience is a biotech company focused on developing cell rejuvenation therapies to defeat the diseases of aging through novel gene-based interventions.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly-appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that make the company's contract development and manufacturing relationship with Forge Biologics go. From CDMO selection to contracting and execution, the episode is packed with actionable insight into building a foundation for collaborative success in advanced biologic therapy development. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

It's been nearly twenty years since 23andMe, the consumer health company was founded. Since then, other companies have emerged, and in exchange for a tube of spit, a puff of breath, or a drop of blood, consumers can now not only find their ancestry and long-lost relatives, but learn what to eat that day or discover food sensitivities and propensity for diseases. But are these tests effective and what are the pitfalls of using a company you found on Instagram to test whether you're likely to suffer from Alzheimer's or cancer? And when those companies cease to exist, as troubled 23andMe might, what happens to all that health data? It's one thing to share your email address or mobile number, and an entirely different proposition to share your genome. We'll talk to experts about the world of consumer DNA-testing and how to protect yourself and your genome. Guests: Kristen V. Brown, staff writer, Atlantic Magazine Hank Greely, law professor; founding director, Center for Law and the Biosciences, Stanford University